On 24 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 79/2024 on the evaluation of the drug Cablivi (caplacizumab) under the drug program: “Treatment of patients with immune thrombotic thrombocytopenic purpura (ICD-10: M31.1)”
Publication in Public Information Bulletin (BIP) >>